trending Market Intelligence /marketintelligence/en/news-insights/trending/o2p0_4hnctan-ocskj82zw2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Osmotica Pharmaceuticals seeks to raise $46.6M through IPO

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Osmotica Pharmaceuticals seeks to raise $46.6M through IPO

Osmotica Pharmaceuticals plc is selling 6,650,000 ordinary shares at $7 each in its IPO.

The Bridgewater, N.J.-based biopharmaceutical company is seeking to raise about $46.6 million through the offering.

Underwriters have a 30-day option to buy up to 997,500 additional ordinary shares at the IPO price.

Osmotica's stock is scheduled to start trading Oct. 18 on the Nasdaq Global Select Market under the symbol OSMT.

Jefferies, Barclays, RBC Capital Markets and Wells Fargo Securities acted as joint lead book-running managers for the IPO.

Meanwhile, Osmotica also launched a private placement of 2,014,285 ordinary shares, priced at $7 each, to certain existing stockholders.

Osmotica develops and commercializes products that target markets for specialty neurology and women's health. It has two candidates in late-stage development: arbaclofen extended‑release tablets for muscle spasticity in multiple sclerosis patients and RVL‑1201 for the treatment of blepharoptosis, or droopy eyelid.